We are working on the development of next-generation cell therapy products that will utilize the unique properties of umbilical cord blood and peripheral blood, by expanding them in large quantities.

We have succeeded in developing technology for the mass propagation of functional HSCs with blood reconstruction ability. In addition, since the technology does not use animal-derived components such as albumin and cytokines, HSCs can be propagated in large quantities with high quality and at low cost.

In addition to providing new therapeutic options for the HSC transplantation treatments that are being performed today, we are also working on applications in the field of gene therapy, which has seen much active development in recent years.